Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
KIBRA repairs synaptic plasticity and promotes resilience to tauopathy-related memory loss
Grant Kauwe, Kristeen A. Pareja-Navarro, Lei Yao, Jackson H. Chen, Ivy Wong, Rowan Saloner, Helen Cifuentes, Alissa L. Nana, Samah Shah, Yaqiao Li, David Le, Salvatore Spina, Lea T. Grinberg, William W. Seeley, Joel H. Kramer, Todd C. Sacktor, Birgit Schilling, Li Gan, Kaitlin B. Casaletto, Tara E. Tracy
Grant Kauwe, Kristeen A. Pareja-Navarro, Lei Yao, Jackson H. Chen, Ivy Wong, Rowan Saloner, Helen Cifuentes, Alissa L. Nana, Samah Shah, Yaqiao Li, David Le, Salvatore Spina, Lea T. Grinberg, William W. Seeley, Joel H. Kramer, Todd C. Sacktor, Birgit Schilling, Li Gan, Kaitlin B. Casaletto, Tara E. Tracy
View: Text | PDF
Research Article Neuroscience

KIBRA repairs synaptic plasticity and promotes resilience to tauopathy-related memory loss

  • Text
  • PDF
Abstract

Synaptic plasticity is obstructed by pathogenic tau in the brain, representing a key mechanism that underlies memory loss in Alzheimer’s disease (AD) and related tauopathies. Here, we found that reduced levels of the memory-associated protein KIdney/BRAin (KIBRA) in the brain and increased KIBRA protein levels in cerebrospinal fluid are associated with cognitive impairment and pathological tau levels in disease. We next defined a mechanism for plasticity repair in vulnerable neurons using the C-terminus of the KIBRA protein (CT-KIBRA). We showed that CT-KIBRA restored plasticity and memory in transgenic mice expressing pathogenic human tau; however, CT-KIBRA did not alter tau levels or prevent tau-induced synapse loss. Instead, we found that CT-KIBRA stabilized the protein kinase Mζ (PKMζ) to maintain synaptic plasticity and memory despite tau-mediated pathogenesis. Thus, our results distinguished KIBRA both as a biomarker of synapse dysfunction and as the foundation for a synapse repair mechanism to reverse cognitive impairment in tauopathy.

Authors

Grant Kauwe, Kristeen A. Pareja-Navarro, Lei Yao, Jackson H. Chen, Ivy Wong, Rowan Saloner, Helen Cifuentes, Alissa L. Nana, Samah Shah, Yaqiao Li, David Le, Salvatore Spina, Lea T. Grinberg, William W. Seeley, Joel H. Kramer, Todd C. Sacktor, Birgit Schilling, Li Gan, Kaitlin B. Casaletto, Tara E. Tracy

×

Figure 5

CT-KIBRA interacts with and stabilizes PKMζ at synapses in neurons with pathogenic tau.

Options: View larger image (or click on image) Download as PowerPoint
CT-KIBRA interacts with and stabilizes PKMζ at synapses in neurons with ...
(A) Images of HEK293 cells coexpressing GFP (green) with HA-PKMζ and flag-tagged KIBRA variants. The PLA was applied to HEK293 cells using anti-HA and anti-flag antibodies to label only the interacting PKMζ and KIBRA variants (red). Scale bar: 10 μm. (B) Graph of mean PLA intensity quantification from HEK293 cells coexpressing HA-PKMζ with flag-tagged KIBRA variants normalized to PLA intensity of cells with full-length KIBRA expression (n = 15–20 cells/group; ***P < 0.001, 1-way ANOVA, Bonferonni post hoc analyses). See also Supplemental Figure 4. (C–E) HEK293 cells expressing HA-PKMζ with or without CT-KIBRA-flag were treated with CHX to monitor PKMζ degradation for 24 hours or 48 hours. (C) Immunoblots from HEK293 cells treated with CHX. (D) Quantification of PKMζ levels normalized to GAPDH at time 0 before CHX treatment (n = 4 replicates/group; ***P < 0.001, unpaired Student’s t test). (E) Graph showing HA-PKMζ stability in HEK293 cells with or without CT-KIBRA-flag. HA-PKMζ immunoreactivity was normalized to basal levels at time 0 (n = 4 replicates/group; ***P < 0.001, 2-way ANOVA, Bonferonni post hoc analyses). See also Supplemental Figure 5. (F) Coimmunolabeling of endogenous PKMζ (blue) and CT-KIBRA-flag (red) in cultured hippocampal neurons with GFP (green) and tauKQ. CT-KIBRA colocalized with PKMζ in postsynaptic spines (arrows) and within dendrites. Scale bar: 2 μm. (G) Images of PKMζ immunolabeling (cyan) in dendrites from mApple-expressing (red) cultured hippocampal neurons with or without tauKQ and CT-KIBRA expression. PKMζ immunoreactivity was assessed in spines (arrowheads). Scale bar: 5 μm. (H) Graph of mean PKMζ integrated intensity quantified in postsynaptic spines and dendrites normalized to control neurons without tauKQ expression (n = 17 cells/group; *P < 0.05, ***P < 0.001, 1-way ANOVA, Bonferonni post hoc analyses). Values are given as means ± SEM. See also Supplemental Figure 5.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts